Levethyroxine
EMR200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 14 Values) (Safety Population)

Treatment: 
- - - - Test  
- - - - - Reference

Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3x200 µg tablets) levethyroxine new formulation.
Reference: 400 µg (3x133.33 µg tablets) levethyroxine old formulation.
Source: Listing 15.4.5.1
Levothyroxine
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Rando M

Treatment: ● ● ● Test ● ● ● Reference

8: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 660 µg (3*220 µg tablets) levothyroxine new formulation.
Reference: 660 µg (3*220 µg tablets) levothyroxine old formulation.
Source: Listing 15.2.5.2

/project24/ep/blinded/0210899늦/secr/stmt/versioncontrol/primary/scripts/program/main/TL program/Figures/Figure 15.4.2.9.ssg

Document No.09006abfe0865b4e v.0.0
CONFIDENTIAL
INFORMATION
11DEC2016 00.00
759/1628
Subject ID/Random Number:

Treatment: ●●●● Test  ●●●● Reference

Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments.
Test: 600 µg (3x200 µg tablets) levothyroxine new formulation.
Reference: 400 µg (3x100 µg tablets) levothyroxine old formulation.
Source: Listing 15.2.3.2
Levothyroxine
Bioequiv,
EMR200125-001 Page 761 of 1628ulation vs. old formulation
Merck Serono
EMR 200125-001
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for individual subjects.](image)

Treatment:
- Test
- Reference

Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 μg (3×200 μg tablets) levothyroxine new formulation.
Reference: 600 μg (3×200 μg tablets) levothyroxine old formulation.
Source: Listing 15.4.2.5.2

/project24/myp/blinded/310299_mccr/stats/versioncontrol/primary/scripts/program/main/VPL programs/figures/Figure
15.4.2.9.jpg

Document No.99098686886646 v.l.0

CONFIDENTIAL
INFORMATION

11DEC2014 00:21
761/1628
Levothyroxine
EMR 200125-001

Figure 12.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Randon Number:

0 Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments.

Test: 600 µg (3 x 200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3 x 200 µg tablets) levothyroxine old formulation.

Source: Listing M.C. A
Levothyroxine
EMR 200125-001

Figure 15.1.2.3 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 74 Values) (Safety Population)

Subject ID/Random Number: 

Treatment: •••• Test: ———— Reference: 

Subject excluded from PK Population; horizontal lines represent the baseline of the respective treatments.

Test: 600 µg (3x200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3x200 µg tablets) levothyroxine old formulation.
Source: Listing 16.7.2.2

/project/ps/blinded/0210898/psr/logs/statistics/primary/surveys/program/main/YFL programs/figures/figure 15.1.2.3.ps
Levothyroxine
EMR 200125-001

Bioequiv: EMR200125-001 Page 764 of 1628 Evaluation vs. old formulation

Subject ID/Random Number:

Figure 15.6.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 74 Values)

| Safety Population |

<table>
<thead>
<tr>
<th>Total T4 (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>270</td>
</tr>
<tr>
<td>260</td>
</tr>
<tr>
<td>250</td>
</tr>
<tr>
<td>240</td>
</tr>
<tr>
<td>230</td>
</tr>
<tr>
<td>220</td>
</tr>
<tr>
<td>210</td>
</tr>
<tr>
<td>200</td>
</tr>
<tr>
<td>190</td>
</tr>
<tr>
<td>180</td>
</tr>
<tr>
<td>170</td>
</tr>
<tr>
<td>160</td>
</tr>
<tr>
<td>150</td>
</tr>
<tr>
<td>140</td>
</tr>
<tr>
<td>130</td>
</tr>
<tr>
<td>120</td>
</tr>
<tr>
<td>110</td>
</tr>
<tr>
<td>100</td>
</tr>
<tr>
<td>90</td>
</tr>
<tr>
<td>80</td>
</tr>
<tr>
<td>70</td>
</tr>
<tr>
<td>60</td>
</tr>
<tr>
<td>50</td>
</tr>
<tr>
<td>40</td>
</tr>
<tr>
<td>30</td>
</tr>
<tr>
<td>20</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>0</td>
</tr>
</tbody>
</table>

Time Point (h)

-2 -1  0  1  2  3  4  5  6  7 8

Treatment: ●●●● Test ●●●● Reference

Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.1

The image contains a graph showing the concentration-time profiles for levothyroxine, with individual concentration values plotted against time in hours (0 to 8) and total T4 levels in ng/mL (0 to 270). The graph compares test and reference treatments, with horizontal lines indicating the baseline for each treatment group.
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Test</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>●●●</td>
<td>●●●</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 650 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 15.2.1.2

/project24/ep/blinded/0210099_narc/stats/versioncontrol/primary/scripts/program/main/78l_programs/Figures/Figure 15.4.2.9.nas
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Test</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

8 Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments.
Test: 600 µg (3 x 200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3 x 200 µg tablets) levothyroxine old formulation.
Source: Listing I.7.3.2

/project24/ep/blinded/a210852_nsrc/stats/versioncontrol/primary/scripts/program/main/T1E/program/Figures/Figure 15.4.2.9.png

Document No. 9009748855214 v.1.0

CONFIDENTIAL INFORMATION

11582014 05:01
Levithyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 767 of 1628

March 2013
Confidential

Figure 13:4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

![Graph of Total T4 (ng/mL)]

- Treatment: • • • Test
- Reference: — — —

Legend:
- Subjects excluded from PK Population: Horizontal lines represent the Baseline of the respective treatments.
- Test: 600 µg (3*200 µg tablets) levithyroxine new formulation.
- Reference: 600 µg (3*200 µg tablets) levithyroxine old formulation.

Source: Listing 14.4.3.0

/project74/db/blinded/e210899_marc/stats/versioncontrol/primary/scripts/program/main/TFL/programs/figures/Figure 13:4.2.9.sas

Document No.9902babe4085bb66 v1.0

CONFIDENTIAL
INFORMATION

11DEC2014 09:01
767/1628
Subject 10/Random Number:

Total T4 (ng/mL)

T4: Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments. Test: 600 mg [3x200 mg tablets] levothyroxine new formulation. Reference: 600 mg [3x200 mg tablets] levothyroxine old formulation. Source: Listing 16.4.3.2
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Test</td>
</tr>
<tr>
<td>2</td>
<td>Reference</td>
</tr>
</tbody>
</table>

Test: 686 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.

Source: Listing 15.2.5.2

/project24/cp/blinded/c213999_mero/data/versioncontrol/primary/scripts/program/main/T4L/program/Figures/Figure
15.4.2.9.sas

Document No: 0903b5a84086b4e v1.0
CONFIDENTIAL
INFORMATION
11062014 00:03
7691628
Levothyroxine
EMR 2000125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Test</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Treatment:
- Test
- Reference

8: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (2x300 µg tablets) Levothyroxine new formulation.
Reference: 600 µg (3x200 µg tablets) Levothyroxine old formulation.

Source: Listing 16.1.6.2
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: ...

Time Point (h)

Treatment: ●●●● Reference

8: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3×200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3×200 µg tablets) levothyroxine old formulation.
Source: Listing 15.3.5.2

/project/ep/blinded/s210899.xorc/status/versioncontrol/primary/scripts/proposal/main/TL programs/figures/Figure 15.4.2.9.x.x

Document No: 09906b4e5858b6 v1.0
CONFIDENTIAL
INFORMATION
11DEC2014 00:01
771/1678
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

- Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
- Test: 650 pg (3×200 pg tablets) levothyroxine new formulation.
- Reference: 600 pg (3×200 pg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

/project24/wp/public/d210899_mesr/va/strats/strats/primary/scripts/program/main/TL programs/Figures/Figure 15.4.2.9.png
Figure 15.4.1.3 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)

(Safety Population)

Subject ID/Random Number:

Treatment: ●●●● Test ●●●● Reference

Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 660 µg (3x200 µg tablets) levothyroxine new formulation.
Reference: 660 µg (3x120 µg tablets) levothyroxine old formulation.
Source: Listing 15.7.5.2
Levothyroxine
EMR 200125-001

Bioequiv EMR200125-001 Page 774 of 1628 ulation vs. old formulation

Necroh Serono
EMR 200125-001

Figure 15.6.2. # Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Test</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

0: Subjects excluded from PK Population. Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3 x 200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3 x 200 µg tablets) levothyroxine old formulation.

Source: Listing 16.3.2.2

/project24/ep/blank/0210899_serono/sponsors/main/figures/figures/Figure 15.6.2.2.png

Document No:0906060618514545 v1.0

CONFIDENTIAL
INFORMATION

11DEC2014 00:01

774/1628

[Image of graph showing concentration-time profiles]
Levothyroxine EMR 200125-001

Bioequiv EMR200125-001 Page 775 of 1628 New vs. old formulation

Merck Serono
EMR 200125-001

Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Randome Number:

0: Subjects excluded from PK Population; Horizontal Lines represent the Baseline of the respective treatments.
Test: 60 μg (3 x 20 μg tablets) levothyroxine new formulation.
Reference: 600 μg (3 x 200 μg tablets) levothyroxine old formulation.

Source: Listing 16.3.3.2

/project26/ep/blinded/e010899.xwcr/atiaa/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.3.jpg

CONFIDENTIAL INFORMATION
Figure 13.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (For Total T4 Values) [Safety Population]

Subject ID/Randon Number:

Treatment: Test Reference

8: Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments. Test: 600 μg (3x200 μg tablets) levothyroxine new formulation. Reference: 600 μg (3x200 μg tablet(s) levothyroxine old formulation.

Source: Hosting 19.1.0.2

/project/ep/biklined/w010093_marc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 13.4.2.9_s.png

Document No: 09098abc489446 v1.0 CONFIDENTIAL INFORMATION 776/1628
Levothyroxine
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Randome Number:

Treatment: ● Test ● Reference

Subjects excluded from PK Population. Horizontal lines represent the baseline of the respective treatments.

Test: 600 µg (3 x 200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3 x 160 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.3.2

/project/248modes2/12089_merco/state/versioncontrol/primary/scripts/program/main/FTP program/figures/figure 15.4.2.9.jpg
Levothyroxine

Bioequiv: EMR200125-001 Page 779 of 1628 Ilation vs. old formulation

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Randome Number:

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Total T4 (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>200</td>
</tr>
<tr>
<td>1</td>
<td>180</td>
</tr>
<tr>
<td>2</td>
<td>160</td>
</tr>
<tr>
<td>3</td>
<td>140</td>
</tr>
<tr>
<td>4</td>
<td>120</td>
</tr>
<tr>
<td>5</td>
<td>100</td>
</tr>
<tr>
<td>6</td>
<td>80</td>
</tr>
<tr>
<td>7</td>
<td>60</td>
</tr>
<tr>
<td>8</td>
<td>40</td>
</tr>
<tr>
<td>9</td>
<td>20</td>
</tr>
<tr>
<td>10</td>
<td>0</td>
</tr>
</tbody>
</table>

Treatment: ••• Test •••• Reference

Subjects excluded from PK Population. Horizontal lines represent the Baseline of the respective treatments.
Test: 690 µg (3x200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3x200 µg tablets) levothyroxine old formulation.
Source: Listing 15.2.5.2

Document No:0905beb688585b46 v1.0 CONFIDENTIAL INFORMATION 779/1628

11082014 00:01
Levothyroxine
EMR 2000125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 74 Values)
(Safety Population)

Subject ID/Random Number: 1

Treatment: 
Test
Reference

@Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3 x 200 µg tablets) levothyroxine new formulation.
Reference: 400 µg (3 x 200 µg tablets) levothyroxine old formulation.
Source: Listing 10.2.5.2.
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Graph showing concentration-time profiles for Total T4 (ng/mL) with time points from 0 to 2 hours.

- **Treatment:**
  - ● ● ● Test
  - ❌ ❌ ❌ Reference

- Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.
- Test: 600 μg (3×200 μg tablets) levothyroxine new formulation.
- Reference: 600 μg (3×200 μg tablets) levothyroxine old formulation.
- Source: Listing 16.1.3.2

/\project/ep/blinded/e210895_marco/states/versioncontrol/primary/scripts/program/main/Y1L programs/figures/Figure 15.4.2.9.sas
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ● ● ● Test  ■ ■ ■ Reference

Subjects excluded from PK Population: Horizontal lines represent the Baseline of the respective treatments.
Source: Listing 16.7.3.2

Document No.099088be808594v1.0 CONFIDENTIAL INFORMATION 11DEC2014 00:01

EMR 200125-001 Page 782 of 1628
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

**Subject ID/Randon Number:**

![Graph](image-url)

- **Treatment:**
  - Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments.
  - Test: 600 μg (3*200 μg tablets) levothyroxine new formulation.
  - Reference: 600 μg (3*200 μg tablets) levothyroxine old formulation.

Source: Listing 15.2.9.4

Document No: 09060b5d88856046 v1.0

CONFIDENTIAL INFORMATION 7831628
Levothyroxine Bioequiv EMR200125-001 Page 784 of 1628 vs. old formulation

Subject ID/Randome Number: 

Treatment: Test Reference

Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 100 μg (3×33.3 μg tablets) levothyroxine new formulation.
Reference: 60 μg (3×200 μg tablets) levothyroxine old formulation.
Source: Listing 13.2.3.2

/project24/ep/blinded/a210999_merc/stats/versioncontrol/primary/scripts/program/main/tek_programs/figures/Figure 13.4.2.8.png

Document No.09094a008859M46 v1.0 CONFIDENTIAL INFORMATION

11/06/2014 60:61

334/1628
Levothyroxine

Bioequiv EMR200125-001 Page 785 of 1628 Relation vs. old formulation

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Rando Number:

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Test</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

8: Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments.
Test: 600 μg (3×200 μg tablets) levothyroxine new formulation.
Reference: 600 μg (3×200 μg tablets) levothyroxine old formulation.
Source: Listing 16.3.3.2

/project24/ep/blinded/a210899_enc/ori/stats/versioncontrol/primary/scripts/program/main/VE/programs/figures/figure

15.4.2.9.png

Document No. 09082016085664 v.1.8

CONFIDENTIAL INFORMATION 789/16/8
Levothyroxine
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Value) (Safety Population)

Subject ID/Random Number:

8: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3×200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3×200 µg tablets) levothyroxine old formulation.
Source: Listing 16.3.5.2

/project248/eq/blanked/e210099_merc/stats/versioncontrol/primary/scripts/program/main/TXL programs/Figures/Figures_15.4.2.9.sas

Document No.9908bae0858bb46 v1.0
CONFIDENTIAL
INFORMATION
31DEC2014 00:00
785/1622
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 74 Values) (Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Test</th>
<th>Reference</th>
</tr>
</thead>
</table>

6: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 μg (3*200 μg tablets) Levothyroxine new formulation.
Reference: 600 μg (2*300 μg tablets) Levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_neco/stats/versioncontrol/primary/scripts/program/mini/TFL_programs/Figures/Figure 15.4.2.9.sas

Document No: 09000abc8885bc46 v1.0

CONFIDENTIAL INFORMATION
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ●●●● Test ●●●● Reference

Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 15.4.2.8
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Treatment:
- Test
- Reference

Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Reference: 600 μg (3×200 μg tablets) levothyroxine new formulation.
Source: Listing 16.2.5.2

/project24/exp/blinded/c010899_mero/stats/versionscontrol/primary/scripts/program/main/T4/programs/Figures/Figure 15.4.2.9.sas
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

8: Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments.
Test: 600 µg (3 x 200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3 x 200 µg tablets) levothyroxine old formulation.
Source: Listing 15.4.2.8
Figure 15.6.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments.]

6: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 500 µg (3×100 µg tablets) levothyroxine new formulation.
Reference: 680 µg (3×180 µg tablets) levothyroxine old formulation.
Source: Listing 15.6.2.3.2

/project24/ep/blinded/e210898/macro/stats/versioncontrol/primary/scripts/program/main/trt programs/figures/Figure
15.6.2.9.885

Document No. 5003a4bc0a25bb46 v.0.0

CONFIDENTIAL INFORMATION

11/22/2004 08:21

911/1638
Levothyroxine
EMR 200125-001

Figure 15.4.2.3 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ● ● ● ● Test ● ● ● ● Reference

Subjects excluded from PK Population: Horizontal lines represent the baseline of the respective treatments.

Test: 660 µg (3 x 220 µg tablets) levothyroxine new formulation.

Reference: 660 µg (3 x 220 µg tablets) levothyroxine old formulation.

Source: Listing 15.1.5.3

/project24/ep/blinded/e110899_ref/teal/versiocontrol/primary/scripts/project/main/TFL programs/figures/Figure 15.4.2.3.sas

Document No.99350a60b3885b46 v1.0 CONFIDENTIAL INFORMATION

11DEC2014 08:16

EMR 200125-001 Page 792 of 1628
Page 39 of 228
Confidential
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Randome Number:

![Graph showing concentration-time profiles for a study on T4 levels.](image)

- **Treatment:**
  - Test: Measurement of T4 levels in the test group.
  - Reference: Measurement of T4 levels in the reference group.

**Notes:**
- Subjects excluded from PK Population: Horizontal lines represent the Baseline of the respective treatments.
- Test: 600 μg (3*200 μg tablets) levothyroxine new formulation.
- Reference: 669 μg (3*200 μg tablets) levothyroxine old formulation.
- Source: Listing 16.7.5.2

---

Document No: 0000ahed089k66 v1.0
CONFIDENTIAL
INFORMATION

Page 793 of 1628
Levothyroxine Bioequiv EMR200125-001 Page 794 of 1628 Evaluation vs. old formulation

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 74 Values)
(Safety Population)

Subject ID/Randome Number:

8: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 15.4.2.9.9

/project24/ap/b1ind2421099/marc/state/versioncontrol/primary/scripts/progress/main/TPL programas/Figures/Figure

31.4.2.9.9.sas

Document No 6906abs23858846 v1.0  CONFIDENTIAL INFORMATION

11/01/2014 00:00

794/1628
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ●●●● Test ◆◆◆◆ Reference

Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 620 μg (3*200 μg tablets) levothyroxine new formulation.
Reference: 600 μg (3*200 μg tablet) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/wp/blinded/e210899/merc/stats/versioncontrol/primary/scripts/program/asis/TLR programs/figures/figure
15.4.2.9.sas
Figure 13.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

- **Treatment:** ● ● ● ● Test  ● ● ● ● Reference

- Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
- Test: 600 μg (3x200 μg tablets) levothyroxine new formulation.
- Reference: 600 μg (3x200 μg tablets) levothyroxine old formulation.

Source: Listing 23.1.3.2

/project24/ep/blinded/w210999.macro/atata/versioncontrol/primary/scripts/program/main/YFL/programs/Figures/Figure 13.4.2.9.sas

Document No.895209885846 v1.0 CONFIDENTIAL INFORMATION 11DEC2014 00:31
Figure 15.4.2.0 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

- Treatment:  ● ● ● Test  ● ● ● Reference

- Subjects excluded from PK Population; horizontal lines represent the baseline of the respective treatments.
- Test: 600 µg (3×200 µg tablets) levothyroxine new formulation.
- Reference: 600 µg (3×200 µg tablets) levothyroxine old formulation.

Source: Listing 16.2.5.2

Document No.0908bebe8045bb16 v1.0 CONFIDENTIAL INFORMATION 797/1628
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total 74 Values) (Safety Population)

Subject ID/Random Number: 1, 2, 3, 4...

Treatment: ●●●● Test  ↑↑↑↑ Reference

0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 μg (3 × 200 μg tablets) levothyroxine new formulation.
Reference: 600 μg (3 × 200 μg tablets) levothyroxine old formulation.
Source: Listing 15.4.2.9.2

/project/ep/blinded/210099_nerv/state/versioncontrol/primary/scripts/program/main/TPF programs/Figures/Figure

Document No. 09090909080546 v1.0
CONFIDENTIAL
INFORMATION
Levothyroxine

Bioequiv: EMR200125-001 Page 799 of 1628 solution vs. old formulation

Merck Serono
EMR 200125-001
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for T4 levels](image_url)
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:

Graph showing concentration-time profiles for test and reference treatments.

- Treatment:
  - Test
  - Reference

Subjects excluded from PK Population; Horizontal lines represent the baseline of the respective treatments.

Test: 600 μg (3x200 μg tablets) levothyroxine new formulation.

Reference: 600 μg (3x200 μg tablets) levothyroxine old formulation.

Source: Listing 15.4.2.9